Skip to main content

Table 1 Baseline Characteristics of Patients Who Initiated Antiviral Therapy

From: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

CharacteristicsAll GenotypesGenotype 1Genotype 2Genotype 3Genotype 4Genotype 6
All patients10215061631413166
Age, year57.3 ± 11.257.1 ± 11.255.8 ± 11.556.5 ± 10.855.7 ± 13.659.2 ± 11.4
Male, n (%)461 (45.2%)236 (46.6%)8 (50.0%)133 (42.4%)4 (30.8%)77 (46.4%)
Race/Ethnicity, n (%)
 Thai774 (75.8%)402 (79.5%)0282 (90%)3 (23%)84 (50.6%)
 Asian162 (15.9%)71 (14%)6 (37.5%)24 (7.5%)058 (34.9%)
 Others85 (8.3%)33 (6.5%)10 (62.5%)8 (2.5%)10 (77%)24 (14.5%)
Treatment experienced, n (%)472 (46.2%)263 (52%)2 (12.5%)148 (47.1%)7 (53.8%)50 (30.1%)
HBV co-infection, n (%)27 (2.6%)12 (2.4%)1 (6.3%)14 (4.5%)00
HIV co-infection, n (%)21 (2.1%)13 (2.6%)08 (2.5%)00
Liver transplant recipient, n (%)31 (3.0%)16 (3.2%)1 (6.3%)9 (2.9%)1 (7.7%)4 (2.4%)
Hepatocellular carcinoma, n (%)28 (2.7%)10 (2%)1 (6.3%)13 (4.1%)1 (7.7%)3 (1.8%)
Cirrhosis, n (%)521 (51.0%)244 (48.2%)4 (25%)203 (64.6%)7 (53.8%)63 (38%)
Child-Turcotte-Pugh class, n (%)
 A436 (83.7%)219 (90%)2 (50%)157 (77%)4 (57%)54 (86%)
 B78 (15%)25 (10%)2 (50%)42 (21%)3 (43%)6 (9%)
 C7 (1.3%)004 (2%)03 (5%)
MELD score8.1 ± 2.67.8 ± 2.27.2 ± 1.18.7 ± 3.08.5 ± 2.58.0 ± 3.2
Platelet count < 100 × 109/μL, n (%)193 (18.9%)79 (15.6%)084 (26.8%)2 (15%)28 (16.9%)
Albumin < 3.5 g/dL, n (%)182 (17.8%)69 (13.6%)4 (25%)76 (24.2%)5 (38.5%)27 (16.3%)
Total bilirubin > 1.1 mg/dL, n (%)189 (18.5%)87 (17.2%)1 (16.7%)77 (24.5%)3 (23.1%)21 (12.7%)
HCV RNA, mean ×106 IU/mL3.6 ± 5.93.5 ± 6.24.2 ± 6.03.0 ± 4.22.4 ± 3.15.2 ± 7.3
≥2 × 106 IU/mL, n (%)452 (44.3%)228 (45.1%)7 (43.8%)118 (37.6%)4 (30.8%)93 (56.0%)
Creatinine clearance, mL/min/1.73 m2
  ≥ 90424 (41.5%)210 (41.5%)9 (56.3%)126 (40.1%)7 (53.8%)69 (41.6%)
 60–89352 (34.5%)178 (35.2%)4 (25.0%)111 (35.4%)2 (15.4%)56 (33.7%)
 30–5981 (7.9%)40 (7.9%)1 (6.2%)25 (8.0%)3 (23.1%)12 (7.2%)
  < 306 (0.6%)3 (0.6%)01 (0.3%)02 (1.2%)
 Not reported158 (15.5%)75 (14.8%)2 (12.5)51 (16.2%)1 (7.7%)27 (16.3%)